BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 16611086)

  • 1. Ruthenium complexes as anticancer agents.
    Kostova I
    Curr Med Chem; 2006; 13(9):1085-107. PubMed ID: 16611086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
    Babak MV; Ang WH
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment.
    Zhao G; Lin H
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):137-47. PubMed ID: 15777221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
    Bergamo A; Sava G
    Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhodium and its compounds as potential agents in cancer treatment.
    Katsaros N; Anagnostopoulou A
    Crit Rev Oncol Hematol; 2002 Jun; 42(3):297-308. PubMed ID: 12050021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
    Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
    Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruthenium-based chemotherapeutics: are they ready for prime time?
    Antonarakis ES; Emadi A
    Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field.
    Amin A; Buratovich MA
    Mini Rev Med Chem; 2009 Nov; 9(13):1489-503. PubMed ID: 20205631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activity of two novel ruthenium compounds in gastric cancer cells.
    Ramírez-Rivera S; Pizarro S; Gallardo M; Gajardo F; Delgadillo A; De La Fuente-Ortega E; MacDonnell FM; Bernal G
    Life Sci; 2018 Nov; 213():57-65. PubMed ID: 30326218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non platinum metal complexes as anti-cancer drugs.
    Ott I; Gust R
    Arch Pharm (Weinheim); 2007 Mar; 340(3):117-26. PubMed ID: 17315259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation anticancer metallodrugs.
    Komeda S; Casini A
    Curr Top Med Chem; 2012; 12(3):219-35. PubMed ID: 22236158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.
    Montel AM; Dos Santos RG; da Costa PR; Silveira-Lacerda EP; Batista AA; Dos Santos WG
    Biometals; 2017 Apr; 30(2):295-305. PubMed ID: 28258507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond platinums: gold complexes as anticancer agents.
    Nardon C; Boscutti G; Fregona D
    Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
    Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
    J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
    Peacock AF; Sadler PJ
    Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.